DMPK and myotonic dystrophy type 1: Despite successful testing of AON targeting mutant CUG RNA in pre-clinical studies [47], the use of DMPK-specific AON faced with difficulties for the effective delivery to the affected tissues (such as skeletal muscle) in human patients with DM1 [50].